Moving Engineered Organotypic Models Towards the Clinic
Wednesday, April 8, 2020 - 10:45am - 11:00am
In vitro cell-based assays for the prediction of patient-specific cancer response have not been widely adopted. However, it is timely to reevaluate their use, as numerous innovations, including micro-scale organ-on-a-chip models, may improve their predictive power and utility and make them a more attractive alternative to animal models. We are exploring how different levels of organotypic complexity may be leveraged to recapitulate patient response in different disease states. The tradeoffs between the model constraints for clinical use vs. mechanistic studies as well as the challenges of moving these models into the clinic will also be discussed.